Cialis shows promise as prostate cancer treatment

Share this article:
Lilly ICOS said its erectile dysfunction (ED) drug Cialis has shown promise in easing urinary problems from benign enlargement of the prostate in men.
A Phase II study showed "statistically significant improvement" in male patients with the prostate problem, a condition known as benign prostatic hyperplasia (BPH).
The trial lasted 12 weeks and consisted of asking an unspecified number of participants to fill out a seven-item questionnaire to assess the severity of symptoms of BPH and the response to therapy.
Lilly may be hoping to find new indication-related success similar to that experienced by Cialis competitor Viagra, which was granted FDA approval for a new indication under a different name earlier this year. Pfizer's Viagra was re-branded as Revatio to treat pulmonary hypertension, a rare, potentially fatal lung disease, in June.
For the first quarter of 2005, Cialis' share of the U.S. ED market was 21.1 percent, compared with 10.4 percent for Levitra and 65 percent for Viagra, according to IMS Health data.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.